TY - JOUR
AR - NNB-2021-2-102
TI - In silico Analysis of Alkaloids for Therapeutic Use in Treatment of Alzheimer's Disease by Targeting Acetylcholinesterase Enzyme
AU - Muhammad Sibte , Hasan Mahmood
AU - Tiyyaba , Furqan
AU - Muaaz , Karim
AU - Sidra, Batool
JO - Neurology and Neurobiology
PY - 2021
DA - Fri 28, May 2021
SN - 2613-7828
DO - http://dx.doi.org/10.31487/j.NNB.2021.02.02
UR - https://www.sciencerepository.org/in-silico-analysis-of-alkaloids-for-therapeutic-use-in-treatment_NNB-2021-2-102 
KW - Beta carbolines, alkaloids, docking, acetylcholinesterase, inhibitor
AB - Alzheimer’s is a progressive mental deterioration associated with the degeneration of the cognition activities and memory loss. It is considered to be a multifactorial disease. One of the causes of the Alzheimer’s disease is the low concentration of the neurotransmitter named acetylcholine (ACh) at the synaptic cleft. Thus, inhibitor of Acetylcholinesterase (AChE), an enzyme whose function is to degrade the acetylcholine, is proved to be a promising candidate to treat this disease. Among the inhibitors are the natural alkaloids that also have an inhibitory effect on the AChE. In this study we have focused on the simple derivates of beta carbolime (a group of alkaloids) and studied their interaction with AChE via rigid protein-ligand docking approach.